KGKuppan Gokulakrishnan

Kuppan Gokulakrishnan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kuppan Gokulakrishnan has a total of 148 co-authors. Here are the top co-authors by number of shared publications:

  • Viswanathan Mohan

    Department of Diabetology, Madras Diabetes Research Foundation (MDRF), ICMR collaboration centre for diabetes research, Chennai, India

    11 shared publications
  • Muthuswamy Balasubramanyam

    Department of Cell and Molecular Biology, Madras Diabetes Research Foundation, Chennai, India

    7 shared publications
  • Ranjit Mohan Anjana

    Department of Diabetology, Madras Diabetes Research Foundation (MDRF), ICMR collaboration centre for diabetes research, Chennai, India

    7 shared publications
  • Ponnusamy Saravanan

    Warwick Medical School, Warwick Applied Health, University of Warwick, Coventry, UK; Centre for Global Health, University of Warwick, Coventry, UK; Centre for Early Life, University of Warwick, Coventry, UK; Diabetes, Endocrinology and Metabolism, George Eliot Hospital NHS Trust, Nuneaton, UK

    6 shared publications
  • Viswanathan Mohan

    Madras Diabetes Research Foundation, Chennai, India

    6 shared publications
  • Chinnasamy Thirumoorthy

    Department of Neurochemistry, National Institute of Mental Health & Neuro Sciences (NIMHANS), Bangalore, India

    5 shared publications

Latest Publications

  • Kynurenine Pathway Metabolite Levels in Drug Naïve and Risperidone Treated Schizophrenia: Insights From Systemic and Post‐Mortem Brain Tissue Analysis

    by Joyappa Nikhil, Chinnasamy Thirumoorthy, Priyamvada Sharma, Vijay Kumar, Shivarama Varambally, Kuppan Gokulakrishnan

    Kynurenine pathway (KP), the principal route of tryptophan (TRY) metabolism, is implicated in schizophrenia (SCZ), but findings remain inconsistent, particularly regarding peripheral‐central associations and links to immune dysregulation. We measured KP metabolites, cytokines, and metabolic risk factors in serum from drug‐naïve (DN) and risperidone‐treated (RT) SCZ patients versus healthy controls (HC) as well as in post‐mortem brain tissue from an independent cohort by assessing KP metabolites, enzyme expression (mRNA, protein) and cytokine profiles. We recruited a total of 227 participants from the clinical services of a large neuropsychiatric hospital, which included DN SCZ ( n = 66), RT SCZ ( n = 87), and HC ( n = 74). Additionally, brain KP metabolite levels and the mRNA and protein expression of key enzymes and cytokines were evaluated in the dorsolateral prefrontal cortex (DLPFC) samples from the post‐mortem cohort of 10 SCZ patients and 17 controls. KP metabolites were measured using liquid chromatography–tandem mass spectrometry (LC–MS/MS). Both DN and RT groups exhibited significantly reduced TRY ( p < 0.05), elevated kynurenine (KYN), kynurenic acid (KYNA), KYN/TRY ratio and serotonin (SER) in serum ( p < 0.001), alongside higher TNF‐α, and IFN‐γ and lower IL‐10 ( p < 0.001 for both). These alterations were correlated with metabolic risk factors, symptom severity of SCZ, and immune markers, and these remained associated with disease status after adjusting for confounders. Post‐mortem analyses confirmed increased brain KYN ( p < 0.05) and KYNA ( p < 0.001) in the DLPFC of SCZ, accompanied by upregulation of Tryptophan 2,3‐dioxygenase (TDO2) ( p < 0.001) and Kynurenine aminotransferase II (KAT II) ( p < 0.05) expression and elevated pro‐inflammatory cytokines. Our findings provide convergent evidence for KP dysregulation in SCZ, linking immune activation with enhanced change toward KYNA synthesis both systemically and centrally. The observed alterations across independent serum and post‐mortem brain cohorts support the potential relevance of these molecular signatures to SCZ pathophysiology and their possible therapeutic implications. image

  • Placental mitochondrial DNA variants, copy number and telomere length alterations in relation to antenatal depressive symptoms

    by Chinnasamy Thirumoorthy, Rohan Peter Mathew, Mohan Deepa, Uma Ram, Ranjit Mohan Anjana, Muthuswamy Balasubramanyam, Viswanathan Mohan, Ponnusamy Saravanan, Periyasamy Govindaraj, Kuppan Gokulakrishnan

  • Open Access

    Efficacy and Safety of Ayurveda Formulation 'Trikatu' in Dyslipidemia: A Study Protocol for a Prospective Single-Center Randomized Double-Blind Placebo-Controlled Trial (Preprint)

    by Sophia Jameela, Bhavya Bm, Shruti Khanduri, Bhogavalli Chandrashekara Rao, Gokulakrishnan Kuppan, Richa Singhal, Bhagwan Sahai Sharma, Sulochana Bhat, Srikanth Narayanam, Rabinarayan Acharya

  • Open Access

    Precision integrated identification of predictive first-trimester metabolomics signatures for early detection of gestational diabetes mellitus

    by Sapna Sharma, Yalamanchili Venkata Subrahmanyam, Payal Gupta, Sangeetha Vadivel, Mohan Deepa, Ansh Tandon, Sreekumar Sreedevi, Uma Ram, Priyanka Narad, Dharmeshkumar Parmar, et al.

    Background and aim: Gestational diabetes mellitus (GDM), a common pregnancy-related metabolic disorder, often goes undiagnosed until the second trimester, limiting early intervention opportunities. Given the higher prevalence of GDM in India, there is a critical need to investigate metabolomic biomarkers among Asian Indians, who exhibit greater insulin resistance and are predisposed to developing type 2 diabetes at an earlier age. This study aimed to identify early pregnancy metabolomic signatures predictive of GDM. Methods: Among 2115 pregnant women from the STratification of Risk of Diabetes in Early pregnancy (STRiDE) study, we performed untargeted metabolomic profiling using UPLC-MS/MS at early pregnancy (< 16 weeks) plasma samples from 100 women—comprising 50 with GDM and 50 normal (without GDM) based on oral glucose tolerance test (OGTT) at 24–28 weeks. Statistical and machine learning approaches, including logistic regression and random forest (RF), were applied to identify GDM-associated metabolites and construct predictive models. Pathway enrichment analysis was conducted using KEGG database annotations. Results: A total of 49 metabolites were significantly associated with GDM, primarily involving lipid classes such as phosphatidylcholines, sphingomyelins, and triacylglycerols. RF analysis identified a panel of eight metabolites that achieved best predictive performance (AUC 0.880; 95% CI: 0.809–0.951) for GDM. When combined with conventional clinical risk factors, the integrated model showed comparable prediction of GDM with AUC 0.88;: 95% CI: 0.810–0.952). Enrichment analysis highlighted dysregulated pathways including glycerophospholipid and sphingolipid metabolism, autophagy, and insulin resistance. Conclusion: This study demonstrates the utility of early-pregnancy metabolomic profiling for predicting GDM in Indian women. The eight-metabolite panel offers a promising tool for early risk stratification of GDM, warranting validation in diverse populations.


  • Open Access

    Neurosteroid Levels in Pregnancy and Its Implications for Mental Health: A Literature Review

    by Kuppan Gokulakrishnan, Viswanathan Mohan, Bn Srikumar

    Background: Perinatal mood disorders are being increasingly recognised and may have deleterious outcomes for the mother and offspring, underlining the importance of understanding their pathophysiology. Neurosteroids can alter the excitability of neurons through rapid non-genomic actions. Here, we review the changes in neurosteroids across pregnancy and their impact on maternal mental health. Summary: Among the neurosteroids, the most studied is allopregnanolone, followed by 5-DHP in pregnancy. Predominantly, allopregnanolone is shown to be increased across pregnancy with a drop in the post-partum levels. With respect to the mood changes in pregnancy and the role of neurosteroids, there are conflicting reports about pregnanolone and its isomers. However, a few studies reported that lower allopregnanolone levels during mid-pregnancy seem to be associated with an increased risk for postpartum depression (PPD). Key Message: Thus, while there are reports that have examined individual neurosteroids across pregnancy, studies with serial measurements that include comprehensively all neurosteroids throughout pregnancy and their temporal relationship to mood are needed. Such studies will pave the way for a better understanding of the neurobiology of mood disorders in pregnancy. Additionally, it will facilitate the development of novel antenatal tests for potential predictive biomarkers, thus improving clinical decision-making, patient management and evolving appropriate preventive lifestyle interventions/therapeutic measures.


  • Epigenome-wide association study identifies a specific panel of DNA methylation signatures for antenatal and postpartum depressive symptoms

    by Chinnasamy Thirumoorthy, Kuldeep Kumar Sharma, Mohan Deepa, Saravanan Yogaprabhu, Janaki Sneha, Ravikumar Pavithra Rekha, Ulagamadesan Venkatesan, Saite Hemavathy, Joyappa Nikhil, Bettadapura N. Srikumar, et al.


  • Association of early pregnancy telomere length and mitochondrial copy number with gestational diabetes mellitus and depressive symptoms

    by Chinnasamy Thirumoorthy, Ravikumar Pavithra Rekha, Mohan Deepa, Uma Ram, Durai Shalu, Ulagamadesan Venkatesan, Bettadapura N. Srikumar, Ranjit Mohan Anjana, Muthuswamy Balasubramanyam, Viswanathan Mohan, et al.


  • Open Access

    First-trimester DNA Methylome profiling identifies novel predictors for gestational diabetes mellitus in Indian women

    by Kuppan Gokulakrishnan, Chinnasamy Thirumoorthy, Kuldeep Sharma, Uma Ram, Mohan Deepa, Yonas Weldeselassie, Hailemariam Asres, U Venkatesh, B Binukumar, Venkatesan Radha, et al.

    Gestational diabetes mellitus (GDM) poses significant health risks for both mothers and offspring, necessitating early detection strategies. We aimed to identify specific DNA methylation signatures in early pregnancy to enhance GDM prediction. We quantified the Epigenome-wide DNA methylation profiles in 258 individuals with normal fasting glucose at early pregnancy (< 16 weeks), of whom 43% (n=111) developed GDM. We identified a panel of five CpGs (cg10139015, cg23507676, cg11001216, cg04539775, cg04985016) that predicted GDM with an area under the curve (AUC) of 0.82 (sensitivity: 82% and specificity: 77%). Combining these CpGs with maternal risk factors (age, waist-height ratio, family history of diabetes, HbA1c, and blood pressure) achieved the highest predictive ability (AUC = 0.86). Our findings suggest that a panel of 5 CpGs exhibits robust predictive value, highlighting the feasibility of creating a CpG panel to predict GDM as early as the first trimester. This has the potential to enhance diagnostic and preventive strategies for GDM.


  • Circulatory levels of lysophosphatidylcholine species in obese adolescents: Findings from cross-sectional and prospective lipidomics analyses

    by Sapna Sharma, Yalamanchili Venkata Subrahmanyam, Harish Ranjani, Sidra Sidra, Dharmeshkumar Parmar, Sangeetha Vadivel, Shanthini Kannan, Harald Grallert, Dandamudi Usharani, Ranjit Mohan Anjana, et al.


  • Association of pro-inflammatory cytokines, adipokines and hepatokine with incident diabetes in India: a nested case–control study within CARRS cohort

    by Ruby Gupta, Roopa Shivashankar, Dimple Kondal, Kuppan Gokulakrishnan, Shivani A. Patel, Mohammed K. Ali, K. M. Venkat Narayan, Viswanathan Mohan, Nikhil Tandon, Dorairaj Prabhakaran

    Aims To study the association of pro-inflammatory markers with incident diabetes in India. Methods We did a nested case–control study within the CARRS (Centre for Ardiometabolic Risk Reduction in South Asia) cohort. Of the 5739 diabetes-free individuals at the baseline, 216 participants with incident diabetes and 432 age-, gender- and city-matched controls at 2-year follow-up were included. We measured high sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 ( MCP-1), adiponectin, leptin and fetuin-A in the stored baseline blood samples. We did multivariate conditional logistic regression to estimate association of inflammatory markers (as quartiles) and incident diabetes. Covariates were baseline fasting plasma glucose (FPG) and lipids, body mass index (BMI), family history of diabetes, smoking and alcohol use. Results Baseline hsCRP and TNF-α were higher, and IL-6 and adiponectin were lower among cases vs. controls. In multivariate conditional logistic regression models, only quartile-3 (odds ratio [OR]: 2.96 [95% CI:1.39, 6.30]) and quartile-4 (OR: 2.58 [95% CI: 1.15, 5.79]) of TNF-α and quartile-4 of MCP-1 (OR: 2.55 [95% CI: 1.06, 6.16]) were positively associated with diabetes after adjusting for baseline FPG and BMI. These associations did not remain after adjusting for family history. High level (quartile-4) of IL-6 was negatively associated with diabetes after adjusting for all factors (OR: 0.18 [95% CI: 0.06, 0.55]). Conclusions Higher TNF-α and MCP-1 levels and lower IL-6 were associated with higher risk of developing diabetes. Better understanding and potential methods of addressing these biomarkers, especially in relation to family history, are needed to address diabetes in South Asians.